Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 36.60, indicating a potential upside of 65.5% from the current price of HKD 22.12 [2][10]. Core Insights - The company is expected to see a recovery in product sales in the second half of 2025, achieving sustainable profitability for the year. Key catalysts for 2026 include a rebound in oncology/immunology revenue, progress in early clinical trials for ATTC, and significant results from two Phase III trials for Savolitinib [3][6]. - The company’s oncology/immunology business is projected to generate revenue between USD 330 million and USD 450 million in 2026, with a notable rebound in sales expected [6]. - The report highlights the anticipated breakthroughs for the ATTC platform, with several candidates entering clinical trials and potential business development opportunities arising from early clinical data [6]. Financial Projections - Revenue forecasts for 2026 are updated to RMB 645 million, reflecting a 1% increase from previous estimates. The gross profit is projected at RMB 301 million, with a gross margin of 46.7% [5][11]. - The net profit for 2026 is estimated at RMB 56 million, a decrease of 34% from prior forecasts, with a net profit margin of 8.7% [5][11]. - The company is expected to maintain a strong cash position, with cash and cash equivalents projected to be RMB 56 million by the end of 2026 [11][12]. Market Performance - The stock has shown a year-to-date increase of 7.27%, with a 52-week high of HKD 30.55 and a low of HKD 19.08 [5][10]. - The report indicates a significant rebound in sales for the company's products, particularly in overseas markets, with sales of Furmonertinib expected to reach USD 203 million in 2H25, reflecting a 25% increase from the previous half [6]. Valuation - The DCF valuation model estimates the equity value at approximately HKD 36.60 per share for the end of 2026, based on projected free cash flows and a perpetual growth rate of 3% [7]. - The enterprise value is calculated to be approximately USD 4.093 billion, with a net cash position of USD 1.377 billion [7]. Summary of Key Financial Metrics - The company is expected to achieve an EBIT of RMB 18 million in 2026, with a projected EBIT margin of 2.7% [11][12]. - The report outlines a gradual improvement in profitability, with net profit expected to rise to RMB 125 million by 2028, reflecting a net profit margin of 15.4% [11].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 36.60, indicating a potential upside of 65.5% from the current price of HKD 22.12 [2][10]. Core Insights - The company is expected to see a recovery in product sales in the second half of 2025, achieving sustainable profitability for the year. Key catalysts for 2026 include a rebound in oncology/immunology revenue, progress in early clinical trials for ATTC, and significant Phase III results for Savolitinib [3][6]. - The report highlights that the company's oncology/immunology business revenue is projected to reach USD 330-450 million in 2026, with a notable rebound in sales expected [6]. Financial Forecast Changes - Revenue forecasts for 2026 have been adjusted to RMB 645 million, reflecting a 1% increase from previous estimates. The gross profit is forecasted at RMB 301 million, a slight decrease of 2% from prior estimates [5][11]. - The net profit forecast for 2026 has been revised down to RMB 56 million, a 34% decrease from previous estimates, with a net profit margin of 8.7% [5][11]. Sales Performance - In the second half of 2025, the company's oncology product revenue is expected to show a significant rebound, with a 16% increase compared to the first half of 2025. Specifically, sales of Furmonertinib are projected to reach USD 203 million, with year-on-year and quarter-on-quarter increases of 22% and 25%, respectively [6][11]. - The report notes that the sales in the Chinese market are also expected to grow, with a 21% quarter-on-quarter increase in the second half of 2025 [6]. Valuation Model - The DCF valuation model estimates the equity value of the company at approximately HKD 36.60 per share for the end of 2026, based on projected free cash flows and a perpetual growth rate of 3% [7][10].

Stock Performance - The stock price of Hutchison China MediTech (00013) has shown fluctuations over the past week, with a range of -0.51% and a volatility of 5.30% from February 7 to February 13, 2026 [2] - On February 13, the closing price was HKD 23.26, with a daily increase of 0.35% and a trading volume of approximately HKD 55.73 million; the net inflow of funds was HKD 5.205 million [2] - In the same period, the US stock (HCM.OQ) experienced a decline of 2.83%, closing at USD 14.75 on February 12 [2] - Technical indicators show that the MACD histogram remains negative, indicating short-term pressure, while the KDJ indicator suggests signs of oversold recovery [2] Business Developments - The company has achieved several milestones in business progress and global compliance [4] - A board meeting is scheduled for March 5, 2026, to review the annual performance for 2025 [4] - The Phase III study of the novel tyrosine kinase inhibitor, Solitomab, for treating warm antibody autoimmune hemolytic anemia has met its primary endpoint, with plans to submit a new drug application to the National Medical Products Administration of China in the first half of 2026 [4] - The antibody-drug conjugate candidates HMPL-A580 and HMPL-A830 are expected to initiate Phase I clinical trials in 2026 [4] - New drug applications for Vanucizumab and Savolitinib have been accepted and prioritized for review [4] - The Shanghai flagship production base has passed an FDA inspection with "zero 483 deficiencies," strengthening the global supply chain capabilities [4]

Core Viewpoint - The company, Honghua Medical (00013), is set to experience several key events in 2026, including annual performance releases and significant new drug development progress [1]. Financial Performance - The company plans to hold a board meeting on March 5, 2026, to review and approve the annual performance for the year ending December 31, 2025 [2]. Business Development - The Phase III study of the novel spleen tyrosine kinase inhibitor, Solipinib, for the treatment of warm antibody autoimmune hemolytic anemia has met its primary endpoint. The company plans to submit a new drug application to the National Medical Products Administration of China in the first half of 2026 [3]. Product Development Progress - The company's antibody-drug conjugate platform candidates, HMPL-A580 and HMPL-A830, are expected to initiate Phase I clinical trials in 2026. Additionally, recent pipeline advancements include the acceptance and priority review of new drug applications for Vanregatinib and Savolitinib [4].

Core Viewpoint - The announcement by Hutchison China MediTech Limited (00013.HK) regarding the acceptance of the new drug application for Fanregratinib (HMPL-453) by the National Medical Products Administration of China highlights a significant advancement in the treatment options for advanced intrahepatic cholangiocarcinoma (ICC) patients with FGFR2 fusion or rearrangement [1] Company Summary - Hutchison China MediTech Limited has received acceptance for its new drug application for Fanregratinib, a selective oral inhibitor targeting FGFR1, 2, and 3, specifically for adult patients with advanced, metastatic, or unresectable ICC who have previously undergone systemic therapy [1] - The drug application has been prioritized for review by the National Medical Products Administration, indicating its potential significance in the market [1] Industry Summary - Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy originating from the intrahepatic bile duct epithelium, accounting for approximately 8.2% to 15.0% of primary liver cancers, making it the second most common type after hepatocellular carcinoma [1] - The incidence of ICC has been on the rise, with a five-year overall survival rate of about 9% [1] - Approximately 10-15% of global ICC patients have FGFR2 fusion or rearrangement, indicating a specific target population for Fanregratinib [1]